Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.
Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Bonig H, et al. Among authors: holtick u. J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1. J Transl Med. 2023. PMID: 37990219 Free PMC article.
Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.
Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M. Theurich S, et al. Among authors: holtick u. J Clin Oncol. 2016 Apr 20;34(12):e110-6. doi: 10.1200/JCO.2013.50.9471. Epub 2014 Oct 27. J Clin Oncol. 2016. PMID: 25348001 No abstract available.
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Schommers P, Gruell H, Abernathy ME, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, Klein F. Schommers P, et al. Among authors: holtick u. Cell. 2020 Feb 6;180(3):471-489.e22. doi: 10.1016/j.cell.2020.01.010. Epub 2020 Jan 30. Cell. 2020. PMID: 32004464 Free PMC article.
Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy.
Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D, Platzbecker U, Rodríguez-Macías G, Wermke M, Holtick U, Balsalobre P, Middeke JM, Shayegi N, Chemnitz JM, Krause A, Gruner N, Füssel M, Schetelig J, Thiede C, Ehninger G, Hallek M, Díez-Martín JL, Bornhäuser M. Tuve S, et al. Among authors: holtick u. Leukemia. 2011 May;25(5):880-3. doi: 10.1038/leu.2011.11. Epub 2011 Feb 11. Leukemia. 2011. PMID: 21311556 No abstract available.
Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients.
Di Cristanziano V, Affeldt P, Trappe M, Wirtz M, Heger E, Knops E, Kaiser R, Stippel D, Müller RU, Holtick U, Scheid C, Kann M, Kurschat CE, Grundmann F. Di Cristanziano V, et al. Among authors: holtick u. Microorganisms. 2021 Aug 4;9(8):1666. doi: 10.3390/microorganisms9081666. Microorganisms. 2021. PMID: 34442744 Free PMC article.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.
Theurich S, Wennhold K, Wedemeyer I, Rothe A, Hübel K, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M. Theurich S, et al. Among authors: holtick u. Transplantation. 2013 Aug 15;96(3):e16-8. doi: 10.1097/TP.0b013e31829a9258. Transplantation. 2013. PMID: 23917689 No abstract available.
107 results